The correct answer is A) BCR-ABL T315I.

Let me provide some detailed context about this mutation:

The BCR-ABL T315I mutation is the most well-known and clinically significant mutation associated with resistance to Imatinib in chronic myeloid leukemia (CML). This specific point mutation occurs in the BCR-ABL tyrosine kinase domain and is particularly important because:

1. Location: The mutation is located at the threonine 315 position (hence T315I)
2. Mechanism: It creates a steric hindrance that prevents Imatinib from binding to the ATP-binding pocket of the BCR-ABL protein
3. Clinical significance: Patients with this mutation typically have poor response to first-generation tyrosine kinase inhibitors (TKIs) like Imatinib

While the other mutations mentioned are important in different contexts: - JAK2 V617F is associated with myeloproliferative disorders - EGFR L858R is typically found in lung cancer - KRAS G12D is commonly seen in various solid tumors

The T315I mutation remains the most significant mutation conferring Imatinib resistance in CML, often requiring second or third-generation TKIs for effective treatment.

The correct answer is A) BCR-ABL T315I mutation.

Detailed explanation:

The BCR-ABL T315I mutation is the most clinically significant and commonly associated mutation with Imatinib resistance in Chronic Myeloid Leukemia (CML). Here's why:

1. Mechanism: - The T315I mutation occurs at position 315 in the ABL kinase domain - It replaces threonine with isoleucine - This mutation prevents Imatinib from binding to the ATP-binding pocket of BCR-ABL

2. Clinical Significance: - Known as the "gatekeeper" mutation - Causes resistance not only to Imatinib but also to second-generation TKIs (nilotinib and dasatinib) - Associated with poor prognosis

3. Why other options are incorrect: - JAK2 V617F: Associated with polycythemia vera and other myeloproliferative disorders - EGFR L858R: Associated with non-small cell lung cancer - KRAS G12D: Common in pancreatic and colorectal cancers

4. Treatment implications: - Patients with T315I mutation may require alternative treatments like ponatinib - Regular mutation screening is important in CML patients showing signs of resistance

This mutation is particularly important in clinical practice because it helps guide treatment decisions when patients show resistance to first-line therapy.

Genetic Mutation Associated with Imatinib Resistance in CML

The correct answer is A) BCR-ABL T315I.

The BCR-ABL T315I mutation is the most clinically significant and commonly associated mutation with resistance to Imatinib (Gleevec) in chronic myeloid leukemia (CML). This specific point mutation:

• Occurs at position 315 in the ABL kinase domain, substituting threonine with isoleucine
• Creates a structural change that prevents Imatinib from binding to the ATP-binding pocket
• Is often called the "gatekeeper mutation"
• Confers resistance not only to Imatinib but also to most second-generation tyrosine kinase inhibitors (dasatinib, nilotinib)

The other mutations listed are associated with different conditions: - JAK2 V617F: Common in other myeloproliferative neoplasms (not CML) - EGFR L858R: Associated with non-small cell lung cancer - KRAS G12D: Common in pancreatic and colorectal cancers

Third-generation inhibitors like ponatinib were specifically designed to overcome the T315I mutation.

The correct answer is A) BCR-ABL T315I.

Explanation:

The T315I mutation in the BCR-ABL kinase domain is the most clinically significant mutation associated with Imatinib resistance in CML. Here's why:

About the T315I Mutation:

• It's a point mutation where threonine at position 315 is replaced by isoleucine
• Often called the "gatekeeper mutation"
• Occurs in approximately 15-20% of patients who develop Imatinib resistance
• Creates a steric hindrance that prevents Imatinib from binding to the ATP-binding pocket of BCR-ABL

Key Characteristics:

• Confers resistance not only to Imatinib but also to second-generation TKIs (Dasatinib, Nilotinib)
• Patients with this mutation often require alternative treatments like:
• Ponatinib (third-generation TKI specifically effective against T315I)
• Allogeneic stem cell transplantation
• Omacetaxine

Why the Other Options are Incorrect:

• B) JAK2 V617F - Associated with myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia), not CML
• C) EGFR L858R - Found in non-small cell lung cancer
• D) KRAS G12D - Common in pancreatic, colorectal, and other solid tumors

The T315I mutation remains a major clinical challenge in CML management and is routinely tested for when patients show signs of Imatinib resistance.

The correct answer is A) BCR-ABL T315I.

The T315I mutation in the BCR-ABL fusion gene is the most common and clinically significant mutation associated with Imatinib resistance in chronic myeloid leukemia (CML). This mutation occurs when threonine at position 315 is replaced by isoleucine, creating what's known as the "gatekeeper" mutation.

Here's why this mutation is particularly important:

1. Mechanism of resistance: The T315I mutation alters the ATP-binding pocket of BCR-ABL, preventing Imatinib from effectively binding to and inhibiting the enzyme.

2. Multi-drug resistance: This mutation confers resistance not only to Imatinib but also to second-generation tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib.

3. Clinical significance: Patients with this mutation often require treatment with third-generation TKIs like ponatinib or alternative therapies.

The other options are mutations associated with different conditions: - JAK2 V617F: Associated with myeloproliferative neoplasms - EGFR L858R: Found in non-small cell lung cancer - KRAS G12D: Common in various solid tumors, particularly colorectal and pancreatic cancers

The correct answer is A) BCR-ABL T315I.

The T315I mutation in the BCR-ABL kinase domain is the most clinically significant mutation associated with Imatinib resistance in chronic myeloid leukemia (CML). Here's why:

Key Points about BCR-ABL T315I:

"Gatekeeper Mutation" - Located at position 315 in the BCR-ABL kinase domain - Threonine (T) is replaced by isoleucine (I) - Called the "gatekeeper" because it controls access to the ATP-binding pocket

High-Level Resistance - Confers significant resistance to Imatinib - Also resistant to second-generation TKIs (Dasatinib, Nilotinib) - Requires third-generation TKIs like Ponatinib for treatment

Clinical Significance - Found in approximately 15-20% of Imatinib-resistant CML cases - Associated with disease progression and poor prognosis - Requires immediate treatment modification

Why the Other Options Are Incorrect:

• B) JAK2 V617F: Associated with myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia), not CML
• C) EGFR L858R: Lung cancer mutation, unrelated to CML
• D) KRAS G12D: Common in various solid tumors, not specific to CML or Imatinib resistance

The T315I mutation represents a major clinical challenge in CML treatment and is the reason why newer TKIs like Ponatinib were developed specifically to overcome this resistance mechanism.

Answer: A) BCR-ABL T315I

Explanation:

The BCR-ABL T315I mutation is the most commonly associated genetic mutation with resistance to Imatinib in chronic myeloid leukemia (CML).

Why T315I is Significant:

1. "Gatekeeper" Mutation: The T315I substitution occurs at a critical position in the ATP-binding pocket of the BCR-ABL kinase domain

2. Steric Hindrance: The threonine-to-isoleucine substitution creates steric interference that prevents Imatinib (and many other TKIs) from binding effectively

3. Clinical Resistance: This mutation confers resistance not only to Imatinib but also to second-generation TKIs like Dasatinib and Nilotinib

4. Prevalence: It accounts for approximately 15-20% of Imatinib-resistant CML cases

Why Other Options Are Incorrect:

• B) JAK2 V617F: Associated with myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia)
• C) EGFR L858R: Found in non-small cell lung cancer
• D) KRAS G12D: Common in colorectal, lung, and pancreatic cancers

Clinical Management:

Patients with T315I mutation typically require treatment with Ponatinib, a third-generation TKI specifically designed to overcome this resistance, or consideration for allogeneic stem cell transplantation.

The correct answer is A) BCR-ABL T315I.

Explanation:

Imatinib (a tyrosine kinase inhibitor) is a first-line treatment for chronic myeloid leukemia (CML), which is driven by the BCR-ABL1 fusion gene (resulting from the Philadelphia chromosome). However, resistance to Imatinib can develop, often due to mutations in the BCR-ABL kinase domain.

• T315I ("gatekeeper" mutation):
• The most common and clinically significant mutation causing Imatinib resistance.
• It alters the kinase's structure, preventing Imatinib from binding effectively.
• Also confers resistance to other TKIs like dasatinib and nilotinib, except for ponatinib or newer agents.

Why the other options are incorrect:

• B) JAK2 V617F: Associated with myeloproliferative neoplasms (e.g., polycythemia vera), not CML.
• C) EGFR L858R: Linked to lung adenocarcinoma and sensitivity to EGFR inhibitors (e.g., gefitinib).
• D) KRAS G12D: Common in solid tumors (e.g., pancreatic, colorectal cancers) but unrelated to CML.

For resistant CML, testing for BCR-ABL mutations (especially T315I) guides the choice of alternative therapies (e.g., ponatinib, asciminib).

Let me know if you'd like more details!

The genetic mutation most commonly associated with resistance to Imatinib (a first-line tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) is A) BCR-ABL T315I. Here's a detailed explanation:

Why T315I Causes Resistance:

1. Mechanism:
   Imatinib targets the BCR-ABL fusion protein (the driver of CML). The T315I mutation occurs in the kinase domain of BCR-ABL, where a threonine-to-isoleucine substitution at position 315 disrupts a critical hydrogen bond needed for Imatinib binding. This prevents the drug from inhibiting the kinase.

2. Clinical Significance:
   - T315I is the most common "gatekeeper mutation" and accounts for 4–19% of Imatinib-resistant cases.
   - It confers resistance to nearly all first- and second-generation TKIs (e.g., Imatinib, Dasatinib, Nilotinib), except third-generation agents like Ponatinib.
   - Patients with this mutation often require alternative therapies or clinical trials.

Why Other Options Are Incorrect:

• B) JAK2 V617F:
  Associated with myeloproliferative neoplasms (e.g., polycythemia vera), not CML. It does not affect BCR-ABL or Imatinib response.

• C) EGFR L858R:
  A mutation in non-small cell lung cancer (NSCLC) that confers sensitivity to EGFR inhibitors (e.g., Osimertinib). Unrelated to CML.

• D) KRAS G12D:
  Common in solid tumors (e.g., pancreatic, colorectal cancers). It drives resistance to anti-EGFR therapies but has no role in CML.

Key Takeaway:

BCR-ABL T315I is the classic mutation linked to Imatinib resistance in CML. Testing for this mutation (via BCR-ABL kinase domain mutation analysis) is standard in resistant cases to guide therapy changes.
Treatment Alternatives: Ponatinib or allogeneic stem cell transplantation may be considered for T315I-positive patients.

For visual clarity, here's how T315I disrupts Imatinib binding:

(Note: Actual molecular diagrams show steric hindrance from isoleucine preventing drug contact.)

The answer is A) BCR-ABL T315I.

Here's why:

• BCR-ABL T315I: This mutation affects the BCR-ABL fusion gene, which is the hallmark of CML. The T315I mutation specifically substitutes threonine (T) with isoleucine (I) at position 315. This amino acid change occurs in the kinase domain of the BCR-ABL protein, rendering it resistant to the binding and therefore the inhibitory effects of Imatinib and other tyrosine kinase inhibitors (TKIs). This is a particularly problematic mutation because it confers resistance to multiple TKIs, making treatment more challenging.

Let's look at why the other options are incorrect:

• JAK2 V617F: This mutation is commonly associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, but not typically with CML or Imatinib resistance.
• EGFR L858R: This mutation is commonly found in non-small cell lung cancer (NSCLC) and is a target for TKIs like gefitinib and erlotinib, not Imatinib. It plays no significant role in CML.
• KRAS G12D: This mutation is common in various cancers, including pancreatic, colorectal, and lung cancers. It affects the RAS signaling pathway and is not directly related to CML or Imatinib resistance.

Therefore, the BCR-ABL T315I mutation is the most commonly associated with resistance to Imatinib in CML.

The correct answer is A) BCR-ABL T315I.

Here's why:

• BCR-ABL T315I: The T315I mutation in the BCR-ABL kinase domain is the most clinically significant mutation conferring resistance to Imatinib and most other tyrosine kinase inhibitors (TKIs) used to treat CML. The mutation prevents the drug from binding effectively to the BCR-ABL protein.

Let's look at the other options:

• JAK2 V617F: This mutation is commonly associated with myeloproliferative neoplasms (MPNs) like polycythemia vera, essential thrombocythemia, and primary myelofibrosis, not CML.
• EGFR L858R: This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with sensitivity to certain EGFR tyrosine kinase inhibitors.
• KRAS G12D: KRAS mutations, including G12D, are commonly found in various cancers, including colorectal cancer, pancreatic cancer, and lung cancer. They can lead to resistance to EGFR-targeted therapies in some contexts but are not directly related to Imatinib resistance in CML.

Therefore, the T315I mutation in BCR-ABL is the primary genetic mutation associated with Imatinib resistance in CML.

The correct answer is A) BCR-ABL T315I.

Here's why:

• Imatinib is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL protein. The BCR-ABL protein is the product of the Philadelphia chromosome, a genetic abnormality found in CML. Imatinib works by binding to the ATP-binding site of the BCR-ABL protein, preventing it from activating downstream signaling pathways that drive cancer cell growth.
• BCR-ABL T315I Mutation: This mutation occurs in the ATP-binding pocket of the BCR-ABL protein. The T315I mutation causes a change in the amino acid at position 315 from threonine (T) to isoleucine (I). This single amino acid change sterically hinders the binding of imatinib, rendering the drug ineffective. The T315I mutation is often referred to as the "gatekeeper mutation" and is a significant cause of resistance to imatinib.
• Why the other options are incorrect:
  • B) JAK2 V617F: This mutation is commonly associated with myeloproliferative neoplasms (MPNs) like polycythemia vera and essential thrombocythemia, not CML. It affects the JAK2 protein, which is involved in signaling pathways unrelated to the BCR-ABL pathway.
  • C) EGFR L858R and D) KRAS G12D: These mutations are associated with resistance to targeted therapies in other cancers, such as non-small cell lung cancer and various other cancers, but are not typically associated with CML or imatinib resistance. They affect different protein targets (EGFR and KRAS, respectively) and signaling pathways.

In summary: The BCR-ABL T315I mutation is the most common and clinically significant mutation associated with resistance to imatinib in CML. If you are concerned about cancer, please consult a healthcare professional for proper diagnosis and treatment.

Ahoj! To je skvělá otázka z oblasti onkologie a molekulární biologie.

Nejčastěji spojovaná genetická mutace s rezistencí na Imatinib u chronické myeloidní leukémie (CML) je A) BCR-ABL T315I.

Pojďme si to trochu rozebrat:

• Imatinib je lék, který patří do skupiny tyrosinkinázových inhibitorů (TKI). Funguje tak, že cílí na fúzní protein BCR-ABL, který je zodpovědný za nekontrolovaný růst buněk u CML.
• Mutace BCR-ABL T315I je konkrétní změna v genu BCR-ABL, kde je aminokyselina threonin (T) na pozici 315 nahrazena isoleucinem (I). Tato mutace je zvláště problematická, protože mění vazebné místo pro Imatinib (a některé další TKI), čímž brání léku v efektivním navázání a inhibici BCR-ABL proteinu. Je známá jako "gatekeeper" mutace a způsobuje vysokou úroveň rezistence.

Proč ostatní možnosti nejsou správné:

• B) JAK2 V617F: Tato mutace je primárně spojena s myeloproliferativními onemocněními, jako je polycythemia vera, esenciální trombocytémie a primární myelofibróza, nikoli s rezistencí na Imatinib u CML.
• C) EGFR L858R: Tato mutace se nachází v genu pro epidermální růstový faktor receptor (EGFR) a je spojena s citlivostí na některé EGFR TKI u nemalobuněčného karcinomu plic, ne s CML.
• D) KRAS G12D: Mutace v genu KRAS jsou běžné u různých typů rakoviny, včetně kolorektálního karcinomu, karcinomu slinivky břišní a plic, ale nejsou spojeny s rezistencí na Imatinib u CML.

Takže, správná odpověď je jednoznačně BCR-ABL T315I. Je to klíčová mutace, kterou lékaři hledají, když pacienti s CML přestanou reagovat na Imatinib.

That's an excellent and very specific question about chronic myeloid leukemia (CML) treatment!

The correct answer is A) BCR-ABL T315I.

Here's a little more detail on why:

• Imatinib is a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, which is the hallmark of CML. It works by fitting into a binding pocket on the BCR-ABL protein, preventing it from signaling and causing cancer cell growth.
• The T315I mutation is a specific change in the BCR-ABL gene (Threonine at position 315 is replaced by Isoleucine). This particular amino acid substitution occurs in the kinase domain of the BCR-ABL protein, right where Imatinib (and some other TKIs) needs to bind. The change in shape caused by the T315I mutation sterically hinders Imatinib from binding effectively, leading to drug resistance. This is often referred to as the "gatekeeper" mutation because of its critical location.

Let's look at why the other options are less likely in this context:

• B) JAK2 V617F: This mutation is commonly associated with other myeloproliferative neoplasms like polycythemia vera, essential thrombocythemia, and primary myelofibrosis, not typically with Imatinib resistance in CML.
• C) EGFR L858R: This mutation is found in the Epidermal Growth Factor Receptor (EGFR) gene and is associated with non-small cell lung cancer and sensitivity to EGFR-targeted therapies.
• D) KRAS G12D: This is a common oncogenic mutation in the KRAS gene found in various cancers like pancreatic, colorectal, and lung cancer, but not the primary driver of Imatinib resistance in CML.

So, the BCR-ABL T315I mutation is indeed the most notorious for causing resistance to Imatinib (and some other first and second-generation TKIs) in CML patients.

Hope this helps clarify things! Let me know if you have any more questions.

The correct answer is: A) BCR-ABL T315I

Explanation: - Imatinib is a tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein produced by the Philadelphia chromosome in chronic myeloid leukemia (CML). - Resistance to Imatinib most commonly develops due to mutations in the BCR-ABL kinase domain. - Among these, the T315I mutation in BCR-ABL is the most notorious, as it confers a high level of resistance to Imatinib and some other tyrosine kinase inhibitors.

Other options: - B) JAK2 V617F — seen in myeloproliferative neoplasms such as polycythemia vera, not related to Imatinib resistance or CML. - C) EGFR L858R — found in some non-small cell lung cancers, not related to CML or Imatinib. - D) KRAS G12D — an oncogenic mutation found in several cancers, especially colorectal cancer and pancreatic cancer, not related to CML.

Summary: BCR-ABL T315I is the genetic mutation most commonly associated with resistance to Imatinib in CML.

The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is:

A) BCR-ABL T315I

Explanation: - Imatinib targets the BCR-ABL tyrosine kinase produced by the BCR-ABL fusion gene in CML. - The T315I mutation in the BCR-ABL gene results in a threonine-to-isoleucine substitution at position 315, which prevents Imatinib from effectively binding to the kinase, leading to resistance. - The other mutations listed are associated with different cancers or pathways: - JAK2 V617F is linked to myeloproliferative disorders like polycythemia vera. - EGFR L858R is common in non-small cell lung cancer. - KRAS G12D is found in various cancers, including pancreatic and colorectal cancer.

So, the correct answer is A) BCR-ABL T315I.

The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is A) BCR-ABL T315I.

This mutation occurs within the BCR-ABL fusion gene, which is the target of Imatinib. The T315I mutation results in a substitution of threonine (T) with isoleucine (I) at amino acid position 315. This change alters the binding site of Imatinib, effectively preventing the drug from binding to BCR-ABL and rendering it ineffective. As a result, patients with this mutation often develop resistance to Imatinib and may require alternative therapies or second-generation tyrosine kinase inhibitors.

Here’s a brief overview of the other options: - JAK2 V617F: Commonly associated with other myeloproliferative neoplasms like polycythemia vera, essential thrombocythemia, and primary myelofibrosis, but not directly linked to Imatinib resistance in CML. - EGFR L858R: A mutation in the epidermal growth factor receptor (EGFR) associated with non-small cell lung cancer, not CML. - KRAS G12D: A mutation involved in several cancers, including colorectal and pancreatic cancers, but not specifically related to CML or Imatinib resistance.

In summary: The correct answer is A) BCR-ABL T315I.

The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is A) BCR-ABL T315I. This mutation occurs in the BCR-ABL fusion oncogene and is known as the "gatekeeper" mutation, which alters the binding site for Imatinib, making the kinase domain resistant to the drug. JAK2 V617F, EGFR L858R, and KRAS G12D are mutations associated with other cancers and conditions.

The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is A) BCR-ABL T315I. This mutation is known to confer a significant resistance to Imatinib, which is a tyrosine kinase inhibitor used to treat CML by targeting the BCR-ABL fusion protein. Other mutations in the BCR-ABL gene can also lead to resistance, but T315I is particularly noted for being resistant to many second-generation tyrosine kinase inhibitors as well.

The other options you mentioned—JAK2 V617F, EGFR L858R, and KRAS G12D—are associated with different cancers and are not directly linked to resistance to Imatinib in CML. If you have any further questions or need clarification, feel free to ask!

A) BCR-ABL T315I

The T315I “gatekeeper” mutation in BCR-ABL is the most commonly associated with imatinib resistance in CML and confers high-level resistance to several TKIs.

A) BCR-ABL T315I

Explanation: The T315I "gatekeeper" mutation in the BCR‑ABL kinase domain prevents imatinib (and many other ABL inhibitors) from binding effectively, and is a well-known cause of acquired resistance in CML. The other listed mutations occur in different cancers or pathways (JAK2 V617F in myeloproliferative neoplasms, EGFR L858R in lung cancer, KRAS G12D in various solid tumors).

Odpověď: A) BCR-ABL T315I

Vysvětlení: Imatinib cílí BCR-ABL fuse protein u CML. Nejčastější mutací, která vede k rezistenci vůči imatinibu (a mnoha dalším TKIs), je mutace T315I v BCR-ABL, která změňuje gatekeeper pozici enzymu a snižuje účinnost léku. Ostatní uvedené mutace (JAK2 V617F, EGFR L858R, KRAS G12D) nejsou typicky spojovány s rezistencí k imatinibu v CML.

The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is the BCR-ABL T315I mutation. This mutation occurs in the BCR-ABL gene, which is the target of Imatinib, and it prevents the drug from effectively binding to and inhibiting the protein.

So, the correct answer is A) BCR-ABL T315I.

If you're interested in visualizing how this mutation might look at a molecular level, there's an option called "image generation" in the input form that you can turn on to generate an image!

Hello! The genetic mutation most commonly associated with resistance to Imatinib in chronic myeloid leukemia (CML) is A) BCR-ABL T315I. This mutation in the BCR-ABL kinase domain prevents Imatinib from binding effectively, leading to treatment resistance.

If you're interested in visualizing this mutation or any related concepts, remember there's an option called "image generation" in the input form that you can turn on for a visual representation. Let me know if you need any more information!

I'm glad to help with your question regarding chronic myeloid leukemia (CML) and resistance to Imatinib.

The correct answer is A) BCR-ABL T315I.

Explanation:

Imatinib (Gleevec) is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is the hallmark of CML and drives the uncontrolled proliferation of leukemic cells. However, resistance to Imatinib can develop due to mutations in the BCR-ABL kinase domain, which prevent the drug from binding effectively.

• BCR-ABL T315I is the most commonly associated mutation with Imatinib resistance. This mutation involves a substitution of threonine to isoleucine at position 315 in the kinase domain, altering the binding site and rendering Imatinib ineffective. It is often referred to as the "gatekeeper" mutation and is also associated with resistance to other first- and second-generation tyrosine kinase inhibitors.

Why not the other options?

• B) JAK2 V617F: This mutation is associated with myeloproliferative neoplasms like polycythemia vera, essential thrombocythemia, and primary myelofibrosis, not CML. It is not related to Imatinib resistance.
• C) EGFR L858R: This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with sensitivity or resistance to EGFR tyrosine kinase inhibitors, not CML or Imatinib.
• D) KRAS G12D: This mutation is frequently seen in cancers like colorectal, pancreatic, and lung cancer, driving oncogenic signaling through the RAS pathway. It is unrelated to CML or Imatinib resistance.

Additional Context:

The T315I mutation poses a significant clinical challenge because it confers resistance not only to Imatinib but also to second-generation inhibitors like Dasatinib and Nilotinib. However, third-generation inhibitors like Ponatinib have been developed to overcome this resistance by effectively targeting the T315I mutation.

If you have further questions about CML, Imatinib resistance, or other related topics, feel free to ask! I'm here to help. 😊

Thank you for your question! I'll provide a clear and detailed explanation based on the latest medical knowledge available up to my last training data in 2023 (as I'm an AI and don't have real-time access, but this information remains current as of 2025).

The Most Common Genetic Mutation Associated with Imatinib Resistance in CML

The correct answer is A) BCR-ABL T315I.

Why is this the case?

• Background on CML and Imatinib: Chronic myeloid leukemia (CML) is a type of blood cancer caused by a genetic abnormality called the Philadelphia chromosome, which results in the BCR-ABL fusion gene. This gene produces an abnormal protein that drives uncontrolled cell growth. Imatinib (also known as Gleevec) is a targeted therapy drug that works as a tyrosine kinase inhibitor, specifically blocking the BCR-ABL protein to slow down or stop the cancer's progression. It's been a game-changer for CML treatment since its approval in the early 2000s.

• Resistance to Imatinib: Over time, some patients develop resistance to Imatinib, meaning the drug becomes less effective. This often happens due to mutations in the BCR-ABL gene itself, which alter the protein's structure and prevent Imatinib from binding properly. Among these, the T315I mutation is the most commonly associated with resistance.

• Details on BCR-ABL T315I: This specific mutation involves a change from threonine (T) to isoleucine (I) at position 315 in the BCR-ABL protein. It creates a "gatekeeper" mutation that sterically hinders Imatinib (and some other similar drugs) from attaching to the protein's active site. As a result, the cancer cells can continue to grow unchecked. Studies have shown that T315I is present in about 15-20% of patients who develop resistance to Imatinib, making it the predominant mutation in this context.

• Comparison with the other options:

• B) JAK2 V617F: This mutation is typically linked to other blood disorders, like polycythemia vera or essential thrombocythemia, and isn't directly associated with CML or Imatinib resistance.
• C) EGFR L858R: This is a common mutation in non-small cell lung cancer and affects the EGFR pathway, which is targeted by drugs like erlotinib or osimertinib. It's not relevant to CML or Imatinib.
• D) KRAS G12D: This mutation is often seen in cancers like colorectal or pancreatic cancer and can lead to resistance in treatments targeting other pathways (e.g., EGFR inhibitors), but it doesn't play a role in Imatinib resistance for CML.

What This Means for Patients

If someone with CML develops resistance due to the T315I mutation, doctors might switch to alternative treatments, such as second-generation tyrosine kinase inhibitors (like dasatinib or nilotinib) or third-generation options (like ponatinib, which is effective against T315I). Regular monitoring through genetic testing is crucial for early detection of such mutations.

If you'd like more details on CML, Imatinib, or related topics (like treatment options or clinical trials), just let me know—I'm here to help! 😊

A) BCR-ABL T315I

This mutation in the BCR-ABL kinase domain is one of the most well-known and clinically significant causes of resistance to imatinib (and several other tyrosine kinase inhibitors) in CML patients. If you have more context or follow-up questions about CML treatment or genetics, feel free to ask!

The most commonly identified genetic mutation conferring resistance to Imatinib in chronic myeloid leukemia (CML) is the BCR-ABL T315I mutation. This mutation alters the ATP-binding pocket of the BCR-ABL fusion protein, preventing Imatinib from binding and inhibiting its activity. Thus, the correct choice is A) BCR-ABL T315I.

The mutation most commonly linked to Imatinib resistance in chronic myeloid leukemia is:

A) BCR-ABL T315I

The most common genetic mutation associated with resistance to Imatinib in chronic myeloid leukemia (CML) is the BCR-ABL T315I mutation (option A).

Here's why:

1. BCR-ABL T315I Mutation:
   - This point mutation occurs in the ATP-binding domain of the BCR-ABL tyrosine kinase.
   - It substitutes threonine (T) with isoleucine (I) at position 315, which prevents imatinib from binding effectively.
   - As a result, the T315I mutation is known to confer resistance to imatinib as well as several other tyrosine kinase inhibitors.

2. Other Options Explained:
   - JAK2 V617F: This mutation is commonly associated with myeloproliferative disorders such as polycythemia vera and essential thrombocythemia, not CML.
   - EGFR L858R: This mutation is primarily involved in non-small cell lung cancer (NSCLC) and is a target for EGFR inhibitors.
   - KRAS G12D: This mutation is seen in various malignancies like colorectal cancer, lung cancer, and pancreatic cancer, but not typically in CML.

Thus, among the choices given, the BCR-ABL T315I mutation is the one most closely linked to resistance to imatinib in CML.

The mutation most commonly linked to acquired resistance to imatinib in CML is:

A) BCR-ABL T315I

Explanation:
• Imatinib targets the BCR-ABL tyrosine kinase created by the Philadelphia chromosome translocation.
• The “gatekeeper” T315I point mutation in the BCR-ABL kinase domain prevents imatinib binding, leading to high-level drug resistance.
• JAK2 V617F is associated with myeloproliferative neoplasms such as polycythemia vera, EGFR L858R with non–small cell lung cancer, and KRAS G12D with various solid tumors—not with imatinib resistance in CML.